Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464711 · ClinicalTrials.gov registry record · Phase 4
Brain GABA Levels and Treatment Response in Major Depressive Disorder
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00464711: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00464711 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00464711, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.
Interventions
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464711
The ClinicalTrials.gov registry entry for NCT00464711 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.
NCT00464711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464711 about?
NCT00464711 is a clinical study titled "Brain GABA Levels and Treatment Response in Major Depressive Disorder". This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.
What is the current status of trial NCT00464711?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00464711?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00464711?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.